<DOC>
	<DOCNO>NCT02580006</DOCNO>
	<brief_summary>This Phase I study compare pharmacokinetics , safety pharmacodynamics EPORON EPREX single subcutaneous administration .</brief_summary>
	<brief_title>To Investigate Pharmacokinetics EPORON® EPREX® After Subcutaneous Administration Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Healthy male volunteer age 19~50 time screen Weight 55.0kg~90.0kg BMI 18.0~27.0 Voluntarily participant agree observe precaution write receive complete explanation trial History clinically significant illness relate liver ( include viral hepatitis ) , kidney , nervous system , immune system , respiratory system , endocrine system , cardiovascular system , blood system tumor well mental illness ( mood disorder , obsessivecompulsive disorder , etc . ) Hypersensitivity clinically significant hypersensitivity drug ( e.g . aspirin , antibiotic , etc . ) Those whose result meet one following screen include retest ; Hemoglobin level 12g/dL 17g/dL , Vitamin B12 level 200pg/mL , Ferritin level 21.8ng/mL , Transferrin level 190mg/dL , Reticulocyte , erythrocytes , platelet serum potassium level normal range Positive HIV antibody , HBsAg , HCV ( Hepatitis C Virus ) antibody test Those whose vital sign measure sit position rest 3 minute meet one follow ; Systolic BP 90mmgHg 160mmgHg , Diastolic BP 50mmgHg 100mmgHg , Pulse rate 100 History drug abuse , test positive urine drug screen Administration EPO ( erythropoietin ) , darbepoetin EPO protein supply , immunoglobulin within 3 month schedule first dose Hypersensitivity EPO , darbepoetin excipient test drug anaphylactic reaction towards iron supplement Those receive following diagnosis within 6 month screen ; Hemoglobinopathy ( e.g. , homozygous sicklecell disease , thalassemia kind ) , Chronic uncontrollable inflammatory disease ( e.g. , rheumatoid arthritis , systemic erythematosus ) Those take ETC ( Ethical ) drug herbal medicine within 2 week , OTC ( Overthecounter ) drug vitamin within week schedule first dose ( However , may include trial subject discretion investigator condition satisfactory . ) Those participated clinical trial administer drug within 3 month schedule first dose Those bled 400mL donate blood within 8 week schedule first dose Those continued drinking ( exceed 21 units/week , 1 unit = 10g pure alcohol ) ca n't abstain alcohol trial period Those smoke 10 cigarette daily average last 3 month ca n't renounce smoke trial period Those ingested grapefruit caffeine contain food within 3 day schedule first dose ca n't abstain trial period . Those prepare pregnancy agree contraception trial period Those peculiar eating habit ca n't meals provided hospital Those consider inappropriate trial trial investigator base result clinical laboratory test due reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>